RxDoctor Payments Data

Alan Puls, MD

Interventional Cardiology · Oklahoma City, OKNPI 1962407932

Payments from drug & device makers

$1,784in general payments, 2019–2025

Across 45 payments — averaging $39.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$299
  • Edwards Lifesciences$254
  • Pfizer$182
  • Atricure, Inc.$174
  • Amarin Pharma, Inc.$153
  • Amgen$145
  • plus $577 from 10 others

What the payments were for

  • Food & beverage$1,784100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,784 in reported general payments places this provider in the 15th percentile of 110 interventional cardiology providers in Oklahoma.

See all interventional cardiology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$272,522
Medicare patients
1,528
Services billed
3,886

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban365$352,598
FarxigaDapagliflozin Propanediol134$139,303
XareltoRivaroxaban49$43,264
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$26,077
JardianceEmpagliflozin19$24,434
JanuviaSitagliptin Phosphate27$23,673
Doxazosin Mesylate615$14,711
Atorvastatin Calcium632$13,721
ClopidogrelClopidogrel Bisulfate611$12,442
Pantoprazole Sodium222$8,949
Metoprolol Succinate398$7,973
Potassium Chloride371$6,730
Carvedilol422$6,113
Rosuvastatin Calcium160$5,704
Lisinopril497$4,938

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$182$352,598365 claims
Boehringer IngelheimJardiance$33$24,43419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 110 interventional cardiology providers in Oklahoma.

Other interventional cardiology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →